Laquisa C. Hill

Hematology
6565 Fannin St
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL.

Journal: Blood advances
Published: April 09, 2026

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL.

Journal: Blood advances
Published: April 09, 2026

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Journal: Blood advances
Published: March 09, 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Journal: Blood advances
Published: March 09, 2026

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.

Journal: Blood
Published: February 20, 2026

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.

Journal: Blood
Published: February 20, 2026

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy
Published: December 04, 2025

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene.

Journal: Blood
Published: September 19, 2025

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Journal: Blood
Published: September 19, 2025

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Primary Results From Blood and Marrow Transplant Clinical Trials Network 1702: Clinical Transplant-Related Long-Term Outcomes of Alternative Donor Allogeneic Transplantation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 18, 2025

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.

Journal: Transplantation and cellular therapy
Published: September 03, 2025

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.

Journal: Blood advances
Published: May 06, 2025
Showing 1-12 of 40

Last Updated: 09/26/2026